Gastrointestinal stromal tumors (GISTs), which lack KIT and PDGFRA gene mutations (wild type), are seen mainly in children and respond poorly to standard targeted therapy.
At Asian Cancer Institute, we know how to focus on a personalized approach for such patients to improve outcome. ?How do we do this? We are up to date and know that further genomic testing in such patients helps divide them into three molecular subtypes: SDH-competent and two types of SDH-deficient. For instance, SDH-deficient tumors were selectively localized to the stomach and were associated with an indolent disease course.
With such knowledge, we finetune the management of each patient and can help precise treatment tailored to patients individual needs.